Press releases

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

ORYZON to give updates on corporate progress in January

ORYZON awarded EU grant to further explore the role of iadademstat in oncological immunotherapy approaches

ORYZON presents final data from Phase IIa ALICE trial in unfit AML patients with first-line treatment of iadademstat and azacitidine in oral presentation at ASH-2022

ORYZON announces FDA clearance of IND to initiate a collaborative Phase II basket study with iadademstat in R/R patients with Neuroendocrine carcinomas (NECs)

ORYZON announces oral data presentation at the upcoming 64th American Society of Hematology annual conference

ORYZON to give updates on corporate progress in November

ORYZON reports results and corporate update for quarter ended September 30, 2022

ORYZON to give updates on corporate progress in October

ORYZON to present preliminary blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder